# JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

> **NCT07075419** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Refractory Hepatocellular Carcinoma

## Interventions

- **DRUG:** JDB153
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT07075419
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075419, "JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07075419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*